[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ars Pharmaceuticals Inc (SPRY)

Ars Pharmaceuticals Inc (SPRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 599,665
  • Shares Outstanding, K 99,447
  • Annual Sales, $ 84,280 K
  • Annual Income, $ -171,300 K
  • EBIT $ -216 M
  • EBITDA $ -220 M
  • 60-Month Beta 0.98
  • Price/Sales 6.75
  • Price/Cash Flow N/A
  • Price/Book 45.40

Options Overview Details

View History
  • Implied Volatility 91.86% (+11.85%)
  • Historical Volatility 86.22%
  • IV Percentile 24%
  • IV Rank 12.12%
  • IV High 341.30% on 03/30/26
  • IV Low 57.47% on 08/28/25
  • Expected Move (DTE 22) 1.13 (18.72%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 16
  • Volume Avg (30-Day) 371
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 7,387
  • Open Int (30-Day) 9,217
  • Expected Range 4.91 to 7.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.33
  • Number of Estimates 2
  • High Estimate $-0.27
  • Low Estimate $-0.38
  • Prior Year $-0.52
  • Growth Rate Est. (year over year) +36.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.91 +21.79%
on 08/03/26
6.58 -9.12%
on 08/19/26
+0.22 (+3.82%)
since 07/27/26
3-Month
4.91 +21.79%
on 08/03/26
10.87 -44.99%
on 06/24/26
-2.52 (-29.65%)
since 05/27/26
52-Week
4.91 +21.79%
on 08/03/26
13.46 -55.57%
on 08/28/25
-7.46 (-55.51%)
since 08/27/25

Most Recent Stories

More News
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY

Wall Street called the missed CVS Caremark formulary date a "negative shock" — a securities class action alleges ARS Pharmaceuticals built analyst expectations on a July 1, 2026 coverage timeline...

SPRY : 5.97 (-1.00%)
Robbins LLP Urges Investors of ARS Pharmaceuticals Inc. to Contact the Firm for Information About the SPRY Securities Class Action Lawsuit

Robbins LLP reminds shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities...

SPRY : 5.97 (-1.00%)
Levi & Korsinsky Reminds ARS Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - SPRY

Eric Karas, ARS Pharmaceuticals' Chief Commercial Officer, is named as a defendant in a securities class action alleging investors were misled about the timing of expanded CVS Caremark coverage for neffy...

SPRY : 5.97 (-1.00%)
Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors Seeking Recovery to Contact the Firm Before October 5, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

SPRY : 5.97 (-1.00%)
BAC : 61.42 (-1.30%)
SPRY Investor Alert: ARS Pharmaceuticals Inc. Securities Class Action Notice - Contact SueWallSt

A securities class action alleges ARS Pharmaceuticals' public statements about a July 1, 2026 CVS Caremark formulary effective date were not accompanied by adequate warnings that the decision could...

SPRY : 5.97 (-1.00%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY

NEW YORK , Aug. 20, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals, Inc. ("ARS" or the "Company") (NASDAQ: SPRY).  Such investors...

SPRY : 5.97 (-1.00%)
Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before the Deadline on October 5, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

SPRY : 5.97 (-1.00%)
BAC : 61.42 (-1.30%)
SPRY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in ARS Pharmaceuticals Securities Lawsuit - Contact Levi & Korsinsky

Notice to pension funds, asset managers, and fiduciaries holding ARS Pharmaceuticals (NASDAQ: SPRY): a securities class action alleges the Company misrepresented the timing of expanded CVS Caremark...

SPRY : 5.97 (-1.00%)
Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before the Lead Plaintiff Deadline on October 5, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

SPRY : 5.97 (-1.00%)
BAC : 61.42 (-1.30%)
SPRY Shareholder Alert: ARS Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm

NEW YORK , Aug. 18, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY).

SPRY : 5.97 (-1.00%)

Business Summary

ARS Pharmaceuticals Inc. is dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions which could lead to anaphylaxis. The company is developing neffy(TM) an intranasal epinephrine product in clinical development for patients and their caregivers...

See More

Key Turning Points

3rd Resistance Point 6.61
2nd Resistance Point 6.35
1st Resistance Point 6.19
Last Price 5.97
1st Support Level 5.77
2nd Support Level 5.51
3rd Support Level 5.35

See More

52-Week High 13.46
Fibonacci 61.8% 10.19
Fibonacci 50% 9.19
Fibonacci 38.2% 8.18
Last Price 5.97
52-Week Low 4.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.